Eli Lilly, the global pharmaceutical giant considered one of the leaders of the diabetes drugs industry, has released important data from a clinical trial. Eli Lilly and Co. claim that analysis from two separate phase 3 trials conducted over the last three years could hold hope for patients with diabetic retinopathy.
According to the company, the investigational treatment Ruboxistauri, also known as Arxxant, actively reduces levels of vision loss by 41 per cent, when compared to a placebo drug. The trial was conducted amongst patients suffering from DR.
Of those patients who were treated with Ruboxistaurin only 6.1 per cent suffered vision loss. In contrast, 10.2 per cent of those patients treated with a placebo faced vision loss.
Lilly will now look for approval from the powerful FDA (Food and Drug Administration) after filing an NDA (New Drug Application .) The FDA will review the drug as a priority.
In order to market and sell drugs into the US market, pharmaceutical and biotechnological companies must first gain the approval of the FDA. Drugs that do not pass FDA scrutiny never make it to market, and in this instance can cost the companies thousands in wasted research.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…